HALO Historical Earnings image   This HALO historical earnings page last updated 8/11/2022
HALO Historical Revenue
PeriodHistorical Earnings DateGAAP
Q2 20228/9/20220.15B
Q1 20225/10/20220.12B
Q4 20212/22/20220.10B
Q3 202111/2/20210.12B
Q2 20218/9/20210.14B
Q1 20215/10/20210.09B
Q4 20202/23/20210.12B
Q3 202011/2/20200.07B
Q2 20208/10/20200.06B
Q1 20205/11/20200.03B
Q4 20192/24/20200.05B
Q3 201911/12/20190.05B
Q2 20198/6/20190.04B
Q1 20195/7/20190.06B
Q4 20182/21/201960.23M
Q3 201811/6/201825.56M
Q2 20188/7/201835.20M
Q1 20185/10/201830.87M
Q4 20172/20/2018189.56M
Q3 201711/7/201763.73M
Q2 20178/8/201733.75M
Q1 20175/9/201729.57M
Q4 20162/28/201739.00M
Q3 201611/7/201631.85M
Q2 20168/9/201633.34M
Q1 20165/9/201642.50M
Q4 20152/29/201652.23M
Q3 201511/9/201520.78M
Q2 20158/10/201543.38M
Q1 20155/11/201518.67M
Q4 20143/2/201530.38M
Q3 201411/10/201414.60M
Q2 20148/11/201414.61M
Q1 20145/12/201411.97M
Q4 20132/27/20140.01B
Q3 201311/8/20130.02B
Q2 20138/7/201314.50M
Q1 20135/8/201311.80M
Q4 20122/25/201321.79M
Q3 201211/8/20125.30M
Q2 20128/6/20127.76M
Q1 20125/7/20127.44M
HALO Historical Earnings EPS
PeriodHistorical Earnings DateAdj. EPS
Q2 20228/9/20220.530
Q1 20225/10/20220.470
Q4 20212/22/20220.420
Q3 202111/2/20210.550
Q2 20218/9/20210.660
Q1 20215/10/20210.370
Q4 20202/23/20210.500
Q3 202011/2/20200.250
Q2 20208/10/20200.190
Q1 20205/11/2020-0.040
Q4 20192/24/2020-0.240
Q3 201911/12/2019-0.170
Q2 20198/6/2019-0.100
Q1 20195/7/20190.010
Q4 20182/21/2019-0.01
Q3 201811/6/2018-0.19
Q2 20188/7/2018-0.16
Q1 20185/10/2018-0.19
Q4 20172/20/20180.85
Q3 201711/7/20170.02
Q2 20178/8/2017-0.23
Q1 20175/9/2017-0.26
Q4 20162/28/2017-0.21
Q3 201611/7/2016-0.23
Q2 20168/9/2016-0.21
Q1 20165/9/2016-0.16
Q4 20152/29/20160.03
Q3 201511/9/2015-0.19
Q2 20158/10/20150.02
Q1 20155/11/2015-0.12
Q4 20143/2/2015-0.04
Q3 201411/10/2014-0.16
Q2 20148/11/2014-0.13
Q1 20145/12/2014-0.22
Q4 20132/27/2014-0.19
Q3 201311/8/2013-0.170
Q2 20138/7/2013-0.2
Q1 20135/8/2013-0.17
Q4 20122/25/2013-0.04
Q3 201211/8/2012-0.18
Q2 20128/6/2012-13
Q1 20125/7/2012-0.14
Quotes delayed 20 minutes

Email EnvelopeFree HALO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Halozyme Therapeutics (HALO) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

HARP Historical Earnings
HBIO Historical Earnings
HCA Historical Earnings
HCWB Historical Earnings
HEPA Historical Earnings
HGEN Historical Earnings
HJLI Historical Earnings
HNGR Historical Earnings
HOLX Historical Earnings
HOOK Historical Earnings
What was the record high HALO historical earnings result?
In terms of earnings or revenue, what is the best HALO historical earnings result that Halozyme Therapeutics has ever posted, and when?

✔️Accepted answer: Within our data set, the highest HALO historical earnings result was set in Q4 2017, when Halozyme Therapeutics posted results of 0.85/share. The most successful revenue quarter within our data set was Q4 2017 when Halozyme Therapeutics reported revenue of 189.56M.

What was the lowest Halozyme Therapeutics historical earnings result?
In terms of top line revenue or bottom line earnings per share, what was the lowest HALO has reported, and when?

✔️Accepted answer: Within our data set, the lowest HALO historical earnings result was set in Q2 2012, when Halozyme Therapeutics posted results of -13/share. The smallest revenue quarter within our data set was Q3 2012 when Halozyme Therapeutics reported revenue of 5.30M.

On this page we presented the HALO historical earnings date information for Halozyme Therapeutics. Reviewing that HALO Historical Earnings for the company, we see that the highest historical earnings result in our data set was in Q4 2017, when HALO posted adjusted EPS of 0.85/share. Meanwhile the lowest HALO historical earnings result was in Q2 2012, when HALO posted adjusted EPS of -13/share. Moving to Halozyme Therapeuticss historical revenue numbers, the largest revenue quarter in our data set was seen in Q4 2017 when HALO reported 189.56M in revenue, while the smallest revenue quarter was Q3 2012 when HALO reported 5.30M in revenue.

For self directed investors doing their due diligence on HALO or any other given stock, their research can benefit from looking into all of the Halozyme Therapeutics historical earnings in our data set presented side by side on one page for ease of comparison. Reviewing this historical EPS information can help when projecting future earnings per share, as well as providing important context for pondering whether the historical earnings trajectory justifies the current stock value or not. That's why we bring you HistoricalEarnings.com to make it more convenient for investors to look into Halozyme Therapeutics historical earnings, or the historical earnings information for any stock in our coverage universe. In your continued due diligence investigations, we hope you check out the further links included for historical PE studies, earnings surprises history as well as next earnings dates for HALO. Thanks for visiting, and the next time you need to research HALO historical earnings or those of another stock, we hope our site will come to your mind as your preferred historical earnings, revenue, and EPS research resource of choice.

Recommended: Institutional Holders of GRMY, Top Ten Hedge Funds Holding THAC, RPAY Insider Buying.

 

HALO Historical Earnings | www.HistoricalEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.